ArticleRisk management and healthcare policy2025
Clinical Characteristics and Risk Factors for Progressive Pulmonary Fibrosis in Primary Sjögren's Syndrome: A Case-Control Study.
Article in Risk management and healthcare policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cough burden in progressive pulmonary fibrosis: a systematic review with narrative synthesis.Health and quality of life outcomes · 2026Pooled it
- Incidence and influencing factors of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Low albumin-to-globulin ratio is associated with interstitial lung disease in primary Sjögren's syndrome: a single-center retrospective cohort study with propensity score matching.Rheumatology international · 2026Article
- Interstitial Lung Disease Secondary to Sjogren's Syndrome and Antisynthetase Syndrome: Converging Disease Trajectories.Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the clinical characteristics and identify risk factors associated with progressive pulmonary fibrosis (PPF) in individuals diagnosed with primary Sjögren's syndrome (pSS). Methods: A retrospective case-control study was conducted from individuals with pSS-associated interstitial lung disease (pSS-ILD) registered in the Chinese Rheumatism Data Center between June 2010 and October 2023. Participants were categorized into two groups: those with PPF (pSS-PPF) and those without PPF (pSS-non-PPF). Comparative analyses were performed on clinical manifestations, laboratory parameters, pulmonary function, and treatment history between the two groups. Results: Sixty-six individuals with pSS-ILD were included, of whom 29 met the criteria for PPF. Compared to pSS-non-PPF group, the pSS-PPF group demonstrated a higher rate of expectoration (48.3% vs 16.2%, Conclusion: A baseline DLCO% < 60% is an independent predictor of PPF in individuals with pSS. The developed predictive model shows strong discriminatory ability, while further validation in larger cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.